Analytical Data
-
Gene name
IRF4
- Application
-
Alternative Names
LSIRF; MUM1; NF-EM5; Lymphocyte-specific interferon regulatory factor; Multiple myeloma oncogene 1
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q64287
-
Expression Region
Asp175~His433
-
Molecular Weight
33kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IRF4 (Interferon Regulatory Factor 4) is a member of the IRF family of transcription factors, playing a crucial role in the regulation of immune responses, particularly in lymphocyte differentiation and function. Its significance has been highlighted in various contexts, such as its involvement in the development and activation of B cells, T cells, and dendritic cells. Dysregulation of IRF4 has been implicated in several pathological conditions, including autoimmune diseases and cancers, particularly in multiple myeloma and certain lymphomas. Recent studies have aimed to understand the molecular mechanisms governing IRF4's activity and its interactions with other signaling pathways. The recombinant expression of IRF4 protein allows for in-depth investigations into its functional roles and facilitates the exploration of its potential as a therapeutic target. Understanding the structural and functional properties of IRF4 is critical for elucidating its contributions to immune regulation and disease, providing insights that could lead to novel approaches in immunotherapy and personalized medicine. This background underscores the importance of IRF4 research in the broader context of immunology and oncology, highlighting its potential as a focal point in developing innovative treatment strategies.
